Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design [PDF]
, 2021 Isabella B. Stone +6 more
openalex +1 more source
Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
Медицинский совет, 2018 The article presents the contemporary views of the role of aldosterone in the progression of cardiovascular and renal diseases. It addresses matters related to the efficacy and safety of mineralocorticoid receptor antagonists in patients with chronic ...
A. M. Esayan, A. N. Nimgirova
doaj +1 more source
FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes [PDF]
, 2023 Минара Шамхаловна Шамхалова +2 more
openalex +1 more source
Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in
, 2021 Deewa Zahir +12 more
openalex +1 more source
Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
Медицинский совет, 2014 The review of literature discusses pathogenetic aspects of chronic heart failure and post-infarction remodelling in the heart. The focus is on the role of neurohormonal activation and the important role of aldosterone.
MG Bubnova
doaj +1 more source
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in
, 2021 Su Ern Yeoh +9 more
openalex +1 more source
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion [PDF]
European Heart Journal, 2009 Pre-treatment with mineralocorticoid receptor (MR) antagonists is reported to reduce myocardial infarct size from ischaemia/reperfusion. Here, we tested whether the MR antagonists potassium canrenoate and eplerenone could protect in the more clinically relevant schedule of administration at the end of ischaemia.In all models, hearts were subjected to ...
Katharina, Schmidt +5 more
openaire +2 more sources
The Egyptian Journal of Internal MedicineBackground In cases of heart failure characterized by reduced ejection fraction (HFrEF), heightened levels of aldosterone negatively impact the progression of heart failure.
H. ElSawi, S. Zidan, A. Elborolosy
doaj +1 more source
A short review of primary aldosteronism in a question and answer fashion
Endocrine Regulations, 2018 Objectives. The aim of this study was to present up to date information concerning the diagnosis and treatment of primary aldosteronism (PA). PA is the most common cause of endocrine hypertension.
Farrugia Frederick-Anthony +7 more
doaj +1 more source
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Drug Discontinuation
JACC: Heart Failure, 2020 Serenelli et al. ([1][1]) investigated the effects of mineralocorticoid receptor antagonists (MRAs) on systolic blood pressure (SBP) and outcomes in patients with heart failure with reduced ejection fraction (HFrEF).
Pedro, Marques +4 more
openaire +2 more sources